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Abstract
Objective: Neuronal damage is the morphological substrate of persisting neurological disability. Neurofilaments (Nf)
are cytoskeletal proteins of neurons and their release into cerebrospinal fluid has shown encouraging results as a
biomarker for neurodegeneration. This study aimed to validate the quantification of the Nf light chain (NfL) in blood
samples, as a biofluid source easily accessible for longitudinal studies.
Methods: We developed and applied a highly sensitive electrochemiluminescence (ECL) based immunoassay for
quantification of NfL in blood and CSF.
Results: Patients with Alzheimer’s disease (AD) (30.8 pg/ml, n=20), Guillain-Barré-syndrome (GBS) (79.4 pg/ml,
n=19) or amyotrophic lateral sclerosis (ALS) (95.4 pg/ml, n=46) had higher serum NfL values than a control group of
neurological patients without evidence of structural CNS damage (control patients, CP) (4.4 pg/ml, n=68, p<0.0001
for each comparison, p=0.002 for AD patients) and healthy controls (HC) (3.3 pg/ml, n=67, p<0.0001). Similar
differences were seen in corresponding CSF samples. CSF and serum levels correlated in AD (r=0.48, p=0.033),
GBS (r=0.79, p<0.0001) and ALS (r=0.70, p<0.0001), but not in CP (r=0.11, p=0.3739). The sensitivity and specificity
of serum NfL for separating ALS from healthy controls was 91.3% and 91.0%.
Conclusions: We developed and validated a novel ECL based sandwich immunoassay for the NfL protein in serum
(NfLUmea47:3); levels in ALS were more than 20-fold higher than in controls. Our data supports further longitudinal
studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and
as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.
Citation: Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, et al. (2013) Increased Neurofilament Light Chain Blood Levels in Neurodegenerative
Neurological Diseases. PLoS ONE 8(9): e75091. doi:10.1371/journal.pone.0075091
Editor: Markus Reindl, Innsbruck Medical University, Austria
Received June 5, 2013; Accepted August 8, 2013; Published September 20, 2013
Copyright: © 2013 Gaiottino et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: J. Gaiottino reports no disclosures; N. Norgren is employed by UmanDiagnostics AB, Sweden; R. Dobson, J. Topping, A. Nissim, A.
Malsapina, J.P. Bestwick, A.U. Monsch, A. Regeniter report no disclosures; R.L. Lindberg has received research support from the Swiss MS Society, Swiss
National Science Foundation, European FP6 and IMI JU programs, Roche Postdoc Fellowship Program (RPF-program), unrestricted research grants from
Novartis and Biogen. L. Kappos reports, the University Hospital Basel as employer of Dr. Kappos has received and dedicated to research support fees for
board membership, consultancy or speaking, or grants, in the last 3 years from Actelion, Advancell, Allozyne, Bayer, Bayhill, Biogen Idec, BioMarin, CSL
Behring, Eli Lilly, European Union, GeNeuro, Genmab, Gianni Rubatto Foundation, Glenmark, Merck Serono, MediciNova, Mitsubishi Pharma, Novartis,
Novartis Research Foundation, Novonordisk, Peptimmune, Roche, Roche Research Foundation, Sanofi-Aventis, Santhera, Swiss MS Society, Swiss
National Research Foundation, Teva, UCB, and Wyeth. D. Leppert is an employee of F. Hoffmann-La Roche Ltd. A. Petzold reports no disclosure. G.
Giovannoni has received research grant support from Bayer–Schering Healthcare, Biogen–Idec, GW Pharma, Merck Serono, Merz, Novartis, Teva and
Sanofi–Aventis. He has received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and
data and safety monitoring committees from: Bayer–Schering Healthcare, Biogen–Idec, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, Ironwood,
Merck–Serono, Novartis, Pfizer, Roche, Sanofi–Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals. J. Kuhle has received research
support from the Swiss MS Society, Swiss ALS Society, Protagen AG, Roche and Novartis and served in scientific advisory boards for Genzyme/Sanofi-
Aventis, Merck Serono and Novartis Pharma. His work is supported by an ECTRIMS Research Fellowship Programme and by the “Forschungsfonds” of
the University of Basel, Switzerland. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: j.kuhle@qmul.ac.uk
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e75091
Introduction
Neurofilaments (Nf) are highly specific major structural
proteins of neurons, consisting predominantly of four subunits:
Nf light (NfL), Nf medium (NfM) and Nf heavy (NfH) chain and
alpha-internexin [1]. Nf are released in significant quantity
following axonal damage or neuronal degeneration. Disruption
to the axonal membrane releases Nf into the interstitial fluid
and eventually into cerebrospinal fluid (CSF) and blood.
Therefore, blood Nf levels could be useful for both predicting
and monitoring disease progression and for assessing the
efficacy and/or toxicity of future neuroprotective treatment
strategies.
Several previous studies have demonstrated the presence of
NfH and NfL in CSF, which has been assumed to reflect brain
pathology more accurately than the peripheral blood
compartment [2–12]. However, obtaining longitudinal CSF
samples is considered too invasive outside the clinical trial
arena, precluding the broader clinical use of Nf. In contrast to
CSF, serial blood samples can readily be collected, hence
reliable quantification of NfL in blood would be a major stride
towards a biomarker of the course of neurodegeneration.
Several reports have suggested peripheral blood levels of NfH
as a potential marker of neurodegeneration [13–22]. In contrast
to this, there is only one recent study investigating serum NfL;
this paper examined the relationship between serum NfL and
neurological outcome following cardiac arrest [23].
A commercially available ELISA (UmanDiagnostics NF-light®
assay) uses two highly specific, non-competing monoclonal
antibodies (47:3 and 2:1) to quantify soluble NfL in CSF
samples but it cannot in its present form be used for analysis of
blood samples [24].
We recently compared our highly sensitive
electrochemiluminescence (ECL)-based solid-phase sandwich
immunoassay for NfHSMI35 (adhering to a previously proposed
nomenclature, the soluble fraction of NfH measured is
indicated with the capture antibody in the superscript [8]) with
NfL, determined by the NF-light® assay in CSF samples [6].
Importantly, the conventional ELISA showed higher sensitivity
compared with the ECL-NfHSMI35 immunoassay [25].
The aim of this study was to develop and validate (both
analytically and clinically) a sensitive ECL-based NfL assay
suitable for the quantification of NfL in serum at concentrations
relevant to clinical settings.
Materials and Methods
Antibodies and chemicals
The following mouse antibodies were used: Capture
monoclonal antibody (mAB) 47:3, and the biotinylated detector
mAB 2:1 [10,24]. MSD SULFO-TAGTM labelled streptavidin was
used as detection reagent to generate
electrochemiluminescence (MSD, Gaithersburg, MD). Bovine
serum albumin (BSA), ethylenediaminetetraacetic disodium salt
(EDTA), NaCl, phosphate buffered saline, pH 7.5 (PBS), tris
base and Tween 20 were of analytical grade (Sigma-Aldrich,
Saint Louis, MO).
Standards
Bovine lyophilized NfL was obtained from UmanDiagnostics
(N Norgren). Standards were diluted in tris buffered saline
(TBS) containing 1% BSA, 0.1% Tween 20, pH 7.5 and ranged
from 0 to 10,000 pg/ml. Batch prepared standards were stored
at -80°C.
Patients and Control persons and ethics statement
Written informed consent was obtained from all patients in
accordance with the Declaration of Helsinki, and the study was
approved by the Common Institutional Review Board of the
Cantons of Basel. Paired CSF and serum samples were
collected during routine diagnostic investigations as indicated
by the treating physicians.
Samples were collected and processed at room temperature
within two hours. Serum samples were spun at 2,000 g, CSF
samples at 400 g at room temperature for 10 minutes,
aliquoted in polypropylene tubes and stored at -80°C.
Serum samples from 67 healthy control subjects (HC) were
included in the study. For ethical reasons CSF samples were
not available from these subjects. The group of control patients
(CP) (n=68) consisted of patients who, based on extensive
diagnostic evaluation had no objective clinical, structural
(cranial magnetic resonance imaging, MRI), laboratory (CSF
analysis) or functional (electroencephalography, EEG) deficit.
These patients suffered from tension type headache (n=21),
lower back pain (n=7), psychiatric disorders (n=26) or
miscellaneous non-specific symptoms for which no
neurological explanation could be found (n=14). From two of
these patients there was not enough CSF left for further
analysis. In addition, 49 patients with probable or definite ALS
(for three no serum and for one no CSF sample was available)
[26], probable Alzheimer’s disease (AD) [27], or a Guillain-
Barré syndrome (GBS) (for one no serum sample was
available) (n=20 each) were included (Table 1). The analyst
was blinded to all clinical data.
Table 1. Demographic characteristics of healthy controls,
control patients and patients.
 HC CP AD GBS ALS
N 67 68 20 20 49
Females
(n [%])a 38 (56.7) 41 (60.3) 13 (65.0) 10 (50.0) 14 (28.6)
Age
[years,
median
(IQR)]b
35.0
(28.0-42.0)
38.3
(27.5-46.4)
72.5
(70.1-80.2)
59.6
(39.1-71.7)
62.7
(54.5-70.7)
aThere were less female ALS patients compared to HC (p=0.004), CP (p=0.001)
and AD (p=0.007).
bHC and CP, were younger compared to AD, GBS and ALS (p<0.0001,
respectively). HC: Healthy controls; CP: Control patients; AD: Alzheimer’s disease;
GBS: Guillain-Barré syndrome; ALS: Amyotrophic lateral sclerosis; IQR:
Interquartile range.
doi: 10.1371/journal.pone.0075091.t001
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Analytical procedure
The 96-well plates (Multi-Array® plates, Meso Scale
Discovery, Gaithersburg, MD) include integrated screen-printed
carbon ink electrodes on the bottom of the wells. Coating was
done overnight with 30 µl of capture antibody (mAB 47:3,1.25
µg/ml) diluted in PBS (pH 7.4) at 4°C. All following incubation
steps were done on a plate shaker (800 rpm) and were
preceded by three wash steps with 200 µl of TBS, containing
0.1% Tween 20 (pH 7.5) per well. Non-specific binding sites
were blocked with 100 µl of TBS, containing 3% BSA, per well
for 1h. After washing, 25 µl of TBS containing 1% BSA and
0.1% Tween 20 was added as sample diluent to each well. 25
µl of standard, control or serum/CSF sample was then added in
duplicate and the plate incubated at room temperature (RT) for
2h. After washing, 25 µl of the secondary antibody (mAB 2:1,
0.5 µg/ml) diluted in TBS containing 1% BSA and 0.1% Tween
20 was added to each well and the plate incubated for 1 h at
RT. After washing, MSD SULFO-TAGTM labelled streptavidin
(0.25 µg/ml), diluted in TBS containing 1% BSA and 0.1%
Tween 20, was added and incubated for 1h at RT. Following a
final wash, 150 µl of ECL read buffer (MSD) diluted 1:2 with
distilled water was added and the ECL signal, detected by
photodetectors, measured using the MSD Sector Imager 2400
plate reader. A four-parameter weighted logistic fit curve was
generated, sample concentrations extrapolated and analysed
using the Discovery Workbench 3.0 software (MSD). If
required, samples were appropriately diluted to fall in the range
of the standard curve. Non measurable NfL samples were
reported as 0 pg/ml.
Statistical analysis
Continuous variables were described by their median and
interquartile range (IQR), and categorical variables by numbers
and percentages. Comparison of demographic data was
performed using the Kruskal-Wallis test, and pairwise post-hoc
comparisons using Dunn’s post-test or chi-square test as
appropriate. Serum and CSF levels of NfL were log-
transformed to achieve a normal distribution for subsequent
analysis. To control for age as a potential confounding factor,
an analysis of covariance with age as covariate and disease
group as fixed factor, was performed [7]. Group-specific levels
of NfL were expressed as geometric means with 95%-
confidence intervals. For log-normal variables, the geometric
mean equals the median. Correlations were computed by
determining the Spearman rank correlation coefficient (r). The
cut-off (upper reference range of normal) providing optimal
sensitivity and specificity in distinguishing ALS from HC by
serum NfL was defined by receiver operating characteristic
(ROC) curve analysis. Proportions above and below this cut-off
were compared with the Chi-Square test. A two-sided p-value <
0.05 was considered as significant. P-values of post-hoc
comparisons were adjusted using a Bonferroni correction. All
statistical analyses and graphs were performed using SPSS
(Version 15.0 SPSS, Chicago, IL) and Graph Pad Prism 5.02
for Windows (GraphPad Software, San Diego, CA).
Results
Reproducibility of the standard curve
Figure 1 shows the mean raw counts of 20 consecutive
standard curves in the range of 0-1,000 pg/ml and the resulting
regression line. Individual standard curves showed a high
degree of linearity (R2 = 0.99) (Figure 1).
Figure 1.  Reproducibility of the standard curve.  Reproducibility of 20 consecutive standard curves. The graph shows the mean
counts (dots) ± SD (bars), linear regression line and 5% and 95% confidence interval curves (broken lines) (R2=0.99).
doi: 10.1371/journal.pone.0075091.g001
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Precision and accuracy
Reproducibility (intra-assay variability) and repeatability
(inter-assay variability) of the assay was evaluated with native
serum samples in 10 consecutive assays on independent days.
In four independent samples of native serum the mean
coefficients of variation (CV) of duplicates (intra-assay
precision) for NfLUmea47:3 were 4.9% (12.1 pg/ml, sample 1),
5.5% (39.6 pg/ml, sample 2), 4.1% (83.1 pg/ml, sample 3) and
3.8% (103 pg/ml, sample 4, average: 4.6%). In CSF the mean
intra-assay CVs were 6.0% (569 pg/ml, sample 1), 6.4% (3,645
pg/ml, sample 2), 2.7% (7,501 pg/ml, sample 3) and 6.8%
(12,762 pg/ml, sample 4) averaging at 5.5%. Inter-assay CVs
for serum were 23.6% (sample 1), 16.9% (sample 2), 8.5%
(sample 3), and 10.9% (sample 4, average: 15.0%). In CSF
inter-assay CVs were 10.3% (sample 1), 10.4% (sample 2),
6.7% (sample 3) and 11.7% (sample 4, average: 9.8%).
Recovery rates were tested in 6 serum samples from healthy
volunteers. Recovery of NfL (serum spiked with 50 pg/ml of
HPLC purified bovine NfL) was 72% and 114%. For serum
spiked with 100 pg/ml of NfL it was 81% and 96%, and for
1,000 pg/ml of NfL recovery was 82% and 116%.
Analytical sensitivity and stability of the analyte
Sensitivity (lowest standard above blank) was calculated as
blank signal plus three standard deviations (SD) from 32
assays. The mean blank signal was 138 counts (SD 20.9
counts). The mean signal of the lowest standard (15.6 pg/ml)
was 184.5 counts (SD 23.2): accordingly analytical sensitivity
was defined to be 15.6 pg/ml. We tested the stability of NfL at
room temperature (RT), 4 °C and compared this to samples
stored at -80 °C. Four aliquoted serum samples were frozen at
-80 °C. The aliquots were thawed on days 0, 3 hours before
measurement, days 1, 4 and 8 and stored at RT or 4 °C until
analysis. The measured signals were normalised to the signal
of the day 0. There was no significant change in signal in
samples stored at RT and at 4 °C (RT: day 8: 1.06 ± 0.08
(mean ± SD), p = 0.4063 and 4 °C: day 8: 1.01 ± 0.09, p =
0.1721). Four serum samples were analysed for stability during
freeze-thawing cycles. The samples underwent 1, 2, 3, 4 or 5
freeze-thawing cycles and the signal was normalised to the
sample freeze-thawed once, without any relevant effect of
freeze-thawing on the measured signals (5 freeze-thawing
cycles: 1.03 ± 0.03, p = 0.5076).
Parallelism
We studied parallelism between standards and samples by
reciprocal dilutions of three serum samples and three standard
curves. The obtained signals were normalised to the highest
value within this series (100%). The parallel relationship is
demonstrated in Figure 2, suggesting the absence of
aggregate formation or endogenous binding between NfL and
other blood substrates [28] (Figure 2).
Reference populations
NfL was determined in serum of 67 HC (56.7% females,
median age 35.0 years) and in serum of 68 and CSF of 66 CP
(60.3% female, median age: 38.3 years) (Table 1). Serum
levels between HC (3.3 pg/ml, 2.0-5.3) and CP (4.4 pg/ml,
2.4-8.1) did not differ (p=1.0) and did not correlate with either
age or gender. Conversely, CSF levels in CP correlated with
age (r=0.68, p<0.0001).
Figure 2.  Parallelism between standards and serum dilutions.  Parallelism for NfL between standards (open line, open dots)
and serum (closed line, black squares). The linear regression lines, mean (open dots or black squares) and ±SD are shown.
doi: 10.1371/journal.pone.0075091.g002
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Neurological disease population
A. Serum.  AD (30.8 pg/ml, 22.6-41.9), GBS (79.4 pg/ml,
24.3-259.6) and ALS (95.4 pg/ml, 57.9-157.0) had higher
serum NfL levels compared with HC and CP (AD versus CP:
p=0.002 all other comparisons versus HC and CP: p<0.0001).
NfL levels correlated with age in GBS (r=0.48, p=0.038) and
ALS (r=0.30, p=0.04). In the age-corrected group comparisons
versus HC and CP differences remained significant, except for
the comparisons against AD (Figure 3).
A cut-off level of 26.6 pg/ml (Figure 3) for serum NfL resulted
in a sensitivity of 91.3% and a specificity of 91.0% for
differentiating ALS versus HC. A higher proportion (p<0.0001
for all comparisons) of patients had serum NfL values above
this cut-off: 16/20 (80.0%) in AD, 13/19 (68.4%) in GBS, 42/46
(91.3%) in ALS, compared to HC (6/67, 9.0%).
B. CSF.  NfL levels in AD (1396 pg/ml, 1139-1711), GBS
(1361 pg/ml, 726-2554) and ALS (5513 pg/ml, 4151-7323)
were higher than in CP (324 pg/ml, 282-372, p<0.0001 for all),
and CSF NfL concentrations in ALS were higher than in AD
and GBS (p<0.0001, respectively).
Similar to the serum results, CSF levels of NfL correlated
with age in GBS (r=0.65, p=0.002) and ALS (r=0.30, p=0.048).
After correction for age, a significant difference remained
between GBS (p=0.001) and ALS (p<0.0001), but not AD
(p=1.0) versus CP. Similarly, we confirmed the higher levels in
ALS as compared to AD and GBS (p<0.0001, for both
comparisons) (Figure 4).
C. CSF – serum relationship.  Overall geometric mean
levels in CSF (1,142 pg/ml, 906-1,439) were 96.8-fold higher
than in serum (11.8 pg/ml, 8.5-16.5, p<0.0001; fold-increase in
CSF versus serum: CP: 73.6, AD: 45.3, GBS: 17.1, ALS: 57.8,
p<0.0001, respectively).
Serum and CSF measurements of NfL correlated in the
disease groups (Figure 5a): AD (r=0.48, p=0.033), GBS
(r=0.79, p<0.0001) and ALS (r=0.70, p<0.0001), conversely
this was not seen in CP (r=0.11, p=0.3739) (Figure 5b).
Discussion
A highly sensitive method for the detection of a clinically
relevant biomarker of neurodegeneration has been developed.
Figure 3.  Serum NfL levels in the two reference groups (healthy controls, HC and control patients, CP) and neurological
disease groups.  Patients with a Guillain-Barré syndrome (GBS) (79.4 pg/ml) or Amyotrophic lateral sclerosis (ALS) (95.4 pg/ml)
had higher values compared with HC (3.3 pg/ml; p<0.0001, respectively) and CP (4.4 pg/ml, p<0.0001 and p=0.001). Significances
for comparisons between patients with Alzheimer’s disease (AD) and HC (p<0.0001) and AD and CP (p=0.002) were lost after age
corrections. The horizontal dotted line represents the upper reference range (cut-off value) of 26.6 pg/ml. Geometric mean and 95%
CI are displayed. Dots represent individual samples. P-values are adjusted for age and corrected by Bonferroni method.
doi: 10.1371/journal.pone.0075091.g003
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Importantly, our method allows us to make use of readily
available longitudinal patient blood samples, instead of being
restricted to ethically difficult to obtain CSF samples. One
potential clinical application for serum NfL levels is
demonstrated by the diagnostic sensitivity of 91.3% for ALS, a
rapidly progressive neurodegenerative disease [29,30].
We present the first ECL based solid phase immunoassay
for the NfL protein in blood based on two non-competitive,
monoclonal antibodies. These antibodies have been widely
used and validated in a commercial ELISA for CSF
measurements of NfL (NF-light® assay) [5,24,31]. NfL is
considered to represent the most abundant and also most
soluble Nf subunit [1].
The optimised ECL-NfL assay protocol proved to be highly
accurate (intra-assay CV < 6%, inter-assay CV < 24%),
sensitive (sensitivity 15.6 pg/ml) and demonstrated linearity
and parallelism (Figures 1 and 2) over a wide analytical range
(15.6-10,000 pg/ml). In addition we found NfLUmea47:3 to be
stable in serum [25]. This is relevant for a potential value to
monitor drug effects by serum NfL in ALS where Nf aggregate
formation is a key pathological finding [28]. In contrast to
NfHSMI34 and NfHSMI35, no such aggregates were found for
NfLUmea47:3, essentially overcoming the limitations of the Nf
“hook effect” (matrix effect) [28]. In this context a more than 20-
fold elevation of serum NfLUmea47:3 levels in ALS compared to
HC cannot be overestimated. Interestingly, the fold-differences
between disease groups and CP for serum NfLUmea47:3 was
higher compared to the respective CSF levels (serum/CSF:
ALS: 21.7/17.0; AD: 7.0/4.3 and GBS: 18.0/4,2).
An important and unresolved question is whether or not there
is a relevant correlation between Nf levels and age. If present,
such a relationship would require age dependent cut-off values
[7]. A major limitation to all studies in this field to date
[6,7,11,32–34] is that they have not been powered to
investigate this potential correlation in the CSF, due to lack of
samples from a sufficiently large healthy control group across
all age categories. Again, the availability of the present method
to investigate this in readily available serum samples is highly
relevant. Importantly, we did not find a correlation between
serum NfLUmea47:3 levels and age in either HC or CP. Whether or
not a possible relationship with age exists for ALS, GBS or AD
is questionable, as older patients are often more severely
affected and higher age is the most important prognostic factor
Figure 4.  CSF NfL levels in the reference group (control patients, CP) and neurological disease cohorts.  Patients with
Amyotrophic lateral sclerosis (ALS) (5513 pg/ml) or a Guillain-Barré syndrome (GBS) (1361 pg/ml) had higher levels than CP (324
pg/ml, p<0.0001 and p=0.001). In addition ALS had higher levels than patients with Alzheimer’s disease (AD) (1361 pg/ml) and GBS
(p<0.0001, respectively). Geometric mean and 95% CI are displayed. Dots represent individual samples. P-values are adjusted for
age and corrected by Bonferroni method.
doi: 10.1371/journal.pone.0075091.g004
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Figure 5.  Correlation of serum and CSF NfL measurements.  Serum and CSF measurements of NfL correlated in the disease
groups (A): Alzheimer’s disease (AD) (r=0.48, p=0.033), Guillain-Barré syndrome (GBS) (r=0.79, p<0.0001) and Amyotrophic lateral
sclerosis (ALS) (r=0.70, p<0.0001): overall: r=0.68, p<0.001. Conversely this was not seen in the control patients (CP) (r=0.11,
p=0.3739) (B).
doi: 10.1371/journal.pone.0075091.g005
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in either condition and therefore not independent of the
neurodegeneration related release of NfLUmea47:3.
The absence of the Nf hook-effect is an important analytical
advantage for quantification of the ECL based serum NfLUmea47:3
assay compared to the serum NfHSMI34 and NfHSMI35 ELISA, as
there is no necessity for a time-consuming pre-incubation step
with urea [28]. Given the important prognostic information that
NfH levels provide on a number of clinical conditions, we
anticipate NfLUmea47:3 to be relevant for future studies. Serum
NfLUmea47:3 bears the potential for predicting disease
progression in ALS [15,35,36] and MS [17,18], detecting
particularly disabling acute episodes of optic neuritis or
relapses in MS [16], identifying primary and secondary brain
damage in stroke [22,37], SAH [13], TBI [19,38] and in the
emerging concept of chronic traumatic encephalopathy (CTE)
[20,38]. Like serum NfHSMI35, serum NfLUmea47:3 may also be
exploited as a safety biomarker for recognising neurotoxicity
[21]. There is already data that serum NfL levels are of
comparable prognostic value to NfHSMI35 levels following
cardiac arrest [19,23]. Of note there were no controls and no
analytical validation data from the NfL assay used in one study
[23].
Similar to our previous findings for NfHSMI35 in CSF, a bimodal
distribution of serum NfL levels was seen in patients with GBS
[6]. There are no previous studies on Nf in blood from patients
with GBS. We have earlier shown that CSF levels of NfH are
higher in patients with evidence of axonal damage compared to
those with purely demyelinating GBS, with CSF NfH levels
predictive of outcome [9,39]. Future prospective studies
incorporating detailed longitudinal clinical and
electrophysiological assessments, and sampling are clearly
warranted. These studies will also shed light on the role of
proximal versus more distal axonotmesis and secondary
axonal peripheral degeneration and the relationship of
increased blood NfL levels [40].
Blood levels of Nf have similarly not been investigated in
patients with dementia. In our study the differences in serum
and CSF NfL levels in AD compared to HC and CP (p<0.0001
and p=0.002) lost significance after age and Bonferroni
correction. This is in line with previous investigations where
CSF NfHSMI35 levels were increased, but diagnostic sensitivity,
and hence potential for clinical use of NfH SMI35 was not superior
to that of the benchmark biomarkers total tau, phospho tau, or
amyloid beta 1-42 [41,42]. To explore these questions further
we are currently expanding our database in a larger and well
characterised cohort of AD and control patients.
In summary, we developed and validated a sensitive and
reliable assay for measurements of NfL in human blood
samples. For the first time, we were able to demonstrate
increased blood NfL levels in patients with ALS and GBS.
These differences were more pronounced for the ECL-NfLUmea
47:3 assay than those reported in ALS for NfH in previous
reports [15,36]. Our data support further studies of serum NfL
in well-defined longitudinal cohorts of neurodegenerative
diseases. These studies will show if serum NfL measurements
can be used as a biomarker for disease progression and as an
outcome measure in clinical trials.
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